Introduction

Choroidal osteoma is a rare tumor associated with intraocular bone formation. It is often an incidental finding on routine examination but can also present as a cause of decreased vision. We present the case of a young female with a choroidal osteoma as well as brief review of the literature with regards to the evaluation and management of choroidal osteomas.

Case presentation

A 16 year old female presented to the New England Eye Center with a chief complaint of decreased vision and metamorphopsia in the left eye. The symptoms started three months prior to presentation and remained unchanged from onset. There were no other visual complaints at the time of presentation. She denied any prior ocular history; this was her first eye exam. On review of systems, there was no history of recent or chronic illness such as diabetes mellitus, no steroid use, no recent medication use, no prior eye disease, and no prior history of surgery. The patient also denied any family history of significant vision loss or eye pathology.

Initial work up began with a comprehensive examination of both eyes. Her visual acuity was 20/20 OD, and 20/25-2 OS. Intraocular pressure was measured as 14 OU. Anterior segment exam was unremarkable in both eyes. Dilated fundus examination of the right eye was unremarkable. In the left eye, dilated fundus examination revealed an amelanotic choroidal lesion encompassing the macula with overlying pigment changes at the level of the Retinal Pigmented Epithelium (RPE). Intraretinal hemorrhage and subretinal fluid were observed in the inferior macula (Figure 1).

Ancillary testing to include Optical Coherence Tomography (OCT), intravenous fluorescein angiography, Indocyanine Green (ICG) chorioangiography and B-scan ultrasonography were performed. Intravenous fluorescein angiography (to include autofluorescence) was unremarkable in the right eye but showed a pattern of spickled hyperfluorescence in the left eye (Figure 2). ICG angiography showed early hypofluorescence intermixed with areas of hyperfluorescence (Figure 3). OCT showed distortion of the choroidal anatomy and subretinal fluid in a juxtafoveal location (Figure 4). Ultrasonography revealed high reflectivity of the lesion with shadowing beyond lesion (Figure 5).

The differential diagnosis for yellow or amelanotic choroidal lesions includes Choroidal osteomas; Amelanotic Melanoma (usually seen in middle-aged or older patients without any sex predilection as compared to choroidal osteomas which are typically seen in young females. There is also typically more elevation with less well defined margins with a choroidal melanoma) [1]; Circumscribed choroidal hemangioma (may have overlying fibrous metaplasia, but typically dome-shaped with smooth margins and cystoid changes of the retina) [1]; Choroidal Metastasis (indistinct margins, often associated with serous retinal detachments) [1]; Disciform scar in Age-Related...
Figure 1: Fundus Photos. The right eye (A) is unremarkable with inset showing unremarkable fluorescein angiogram of the same eye. The left eye (B) shows a Yellow/amelanotic Choroidal lesion with overlying Retinal Pigment Epithelium (RPE) pigment changes encompassing the macula with intraretinal hemorrhage and subretinal fluid in the inferior macula.

Figure 2: Fluorescein angiography of the left eye; Red free (A) showing hyper-autofluorescence intermixed with hypo-autofluorescence. Early (B), mid-phase (C), and late phase (D) of intravenous fluorescein angiography showing spickled hyperfluorescence with late staining in areas of thinned RPE.

Figure 3: Indocyanine green angiography images showing early hypofluorescence (A) in areas of the lesion with hyperfluorescence of intralesional vessels. The Mid-phase (B) also reveals hypofluorescence with hyperfluorescence of Intrallesional vessels. Late in the study (C), there is persistent hypofluorescence albeit less pronounced.

Figure 4: Optical coherence tomography shows distortion of the choroidal anatomy and subretinal fluid.

Figure 5: B-scan ultrasonography showing high reflectivity of the lesion with shadowing beyond lesion.
The patient was given an intravitreal injection of bevacizumab as the first of 3 monthly injections. One month later, she had gained one line of vision and was now 20/30 from 20/40-1 at her previous visit. On exam, there was a new area of intraretinal hemorrhage noted on the inferior aspect of the lesion. The second injection of intravitreal bevacizumab was given and she scheduled another one month follow up visit. The following month, her vision was retained at 20/30. There was no new intraretinal hemorrhage on exam. She received the third intravitreal injection and followed up one month later. By this time, the choroidal neovascular membrane had resolved.

**Discussion**

Choroidal osteomas are predominately found in the juxtapapillary and macular region of young women (90%), in the second and third decades of life [1]. They are typically found in otherwise healthy eyes in sharp contrast to other eyes in which bone formation may be found: Phthisis bulbi and cyclitic membranes. They generally occur sporadically with only a few cases of familial choroidal osteomas in the literature [3]. Choroidal osteomas are unilateral 75% of the time [1]. They may be asymptomatic, or may cause visual symptoms such as blurring of vision, metamorphopsia, or visual field defects corresponding to the tumor location [1]. Tumor growth was reported in 41% of 22 cases over 10 years [4] and size ranges have been reported as anywhere from 2-22mm in basal dimension and 0.5-2.5mm in elevation [4]. Decalcification of the tumor may occur spontaneously or may be induced by laser treatment and the rate of partial or complete decalcification is reported as 28% of choroidal osteomas by 5 years and 46% at 10 years [5].

Choroidal Neovascularization (CNV) has been noted in association with choroidal osteomas and is a known cause of late decreased vision [1]. The typical presentation is a complaint of new metamorphopsia or scotoma and a finding of serous or hemorrhagic detachment of the macula is not uncommon. One study found a CNV rate of 22% at 5 years and 51% at 10 years [6] while another study reported a rate of 31% at 5 years, 47% at 10 years and 56% at 20 years [4]. The exact etiology or pathogenesis of CNV in choroidal osteomas remains unclear.

CNV associated with choroidal osteomas is often an indication for treatment due in part to the high association of CNV with decreased vision. Reasons for decreased vision in CNV include subretinal fluid, subretinal hemorrhage, retinal pigment epithelium atrophy and/or photoreceptor atrophy. Some of the treatment modalities previously employed in the treatment of CNV associated with choroidal osteomas include argon laser photocoagulation [7,8], transpupillary thermotherapy (TTT) [9], and Photodynamic Therapy (PDT) 10,11. Surgical evacuation of the choroidal neovascular membrane has been reported [12] but the visual outcome was not favorable. More recently, anti-VEGF agents have become the mainstay in the treatment of choroidal neovascularization associated with various diseases such as age-related macular degeneration, diabetic retinopathy, presumed ocular histoplasmosis syndrome, high myopia, and choroidal osteomas. No large clinical trials have evaluated the use of anti-VEGF for choroidal neovascularization associated with choroidal osteomas; however, a number of case studies have published their findings and have reported improved vision and resolution of CNV.

Our patient gained a line of vision after the first treatment and retained her vision throughout the course of the treatment. At the
time of this publication, the patient had been followed for a little over 12 months and retained visual acuity of 20/30 in the left eye and did not develop any new choroidal neovascularization. She did not enjoy the dramatic improvements in vision seen in some prior reports on the use of bevacizumab in the treatment choroidal osteoma-related CNV. One study showed an improvement in VA from CF at 1.5 meters to 20/125 following 2 treatments of monthly injections of intravitreal bevacizumab (0.5mg) with resolution of the neovascular membrane [13]. Another study showed improvement of VA from 20/125 to 20/25 with regression of the neovascular membrane 6 weeks following one treatment with intravitreal bevacizumab [14]. A point worth noting is the fact that our patient’s presenting visual acuity was not as severely affected as some of the patients in referenced studies. Treatment with ranibizumab has also been reported [15] with improvement in vision and resolution of the neovascular membrane.

Choroidal osteoma is a well-studied rare tumor of the choroid which may be asymptomatic or may lead to impaired vision in some cases. Choroidal neovascularization associated with choroidal osteoma is also well known and can be managed with anti-VEGF agents. Our patient’s response to therapy is consistent with the existing reports on the use of anti-VEGF for the management of CNV in choroidal osteoma. Larger and more robust studies are needed to fully evaluate the use of anti-VEGF in the management of choroidal osteoma-related CNV and to record long-term results, adverse effects if any, and to standardize the treatment regimen if possible.

References